Company news

Achieve Life Sciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Achieve Life Sciences Announces Pricing of $6.5 Million Public Offering

August 3, 2020

Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications

July 30, 2020

Achieve Life Sciences to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020

July 27, 2020

Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering

June 28, 2020

Achieve Announces Successful Results from the Investigator-Initiated RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix® (varenicline) as a Treatment to Quit Smoking

June 28, 2020

Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program

May 13, 2020

Achieve Life Sciences to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 14, 2020

May 4, 2020

Achieve Life Sciences Announces Private Placement of $1.9 Million

April 29, 2020

Achieve Reports Financial Results for Fourth Quarter and Year-End 2019 and Provides Update on Cytisinicline Development Program

March 12, 2020

Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting

March 11, 2020

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2019 Financial Results and Host Conference Call and Webcast on March 13, 2020

March 2, 2020

Achieve Life Sciences Announces Agreement with the FreeMind Group to Assist in Securing Non-Dilutive Funding to Evaluate Cytisinicline in Vaping and e-Cigarette Users

February 5, 2020

Achieve Life Sciences, Inc. Announces Closing of $13.8 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option

December 18, 2019

Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering

December 16, 2019

Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program

December 8, 2019

Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program

November 5, 2019

Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study

September 29, 2019

Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

September 12, 2019

Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial

September 4, 2019

Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences

September 3, 2019

Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update

August 7, 2019

Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation

July 22, 2019

Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

June 20, 2019

Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial

June 10, 2019

Achieve Receives $4.2 Million from Exercise of Warrants

June 2, 2019

Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline

May 29, 2019

Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation

April 23, 2019

Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation

April 1, 2019

← Newer news releases

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.